Alpha Score of 64 reflects moderate overall profile with strong momentum, strong value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Point72 Steve Cohen | 3.21M | $60.93M | NEW |
| ARK Invest Cathie Wood | 1.60M | $30.40M | NEW |
| Citadel Ken Griffin | 1.19M | $22.52M | NEW |
Nurix Therapeutics Inc. is a biotechnology firm focused on developing therapies to address immune system disorders and cancers. At the heart of its innovative approach is the modulation of protein levels within cells, a critical factor in disease progression. Nurix employs its proprietary DELigase platform to discover and design targeted therapies that either enhance or degrade specific proteins through ubiquitin proteasome system engagement. By manipulating the protein degradation pathways, the company aims to offer new treatment paradigms where traditional therapeutics may fall short. Nurix Therapeutics' research and product pipeline significantly influences the biotechnology and pharmaceutical sectors, with emphasis on immuno-oncology, a rapidly growing field within cancer treatment. Formed through scientific expertise and collaborations, the company encapsulates significant market insights by translating breakthroughs in protein homeostasis into potential life-altering therapies, thus playing a pivotal role in advancing personalized medicine.
Earnings calendar coming soon. Subscribe to get notified when NRIX reports next.
Get earnings alerts →